Comparative evaluation of six nucleic acid amplification kits for SARS-CoV-2 RNA detection
Abstract Background SARS-CoV-2 is a newly emerged coronavirus, causing the coronavirus disease 2019 (COVID-19) outbreak in December, 2019. As drugs and vaccines of COVID-19 remain in development, accurate virus detection plays a crucial role in the current public health crisis. Quantitative real-tim...
Saved in:
Main Authors: | , , , , , , , , , , , , , , |
---|---|
Format: | Book |
Published: |
BMC,
2021-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000 am a22000003u 4500 | ||
---|---|---|---|
001 | doaj_aca795eaa5464d6b961fa12a40ce0b51 | ||
042 | |a dc | ||
100 | 1 | 0 | |a Shuang Wu |e author |
700 | 1 | 0 | |a Xiaolu Shi |e author |
700 | 1 | 0 | |a Qiongcheng Chen |e author |
700 | 1 | 0 | |a Yixiang Jiang |e author |
700 | 1 | 0 | |a Le Zuo |e author |
700 | 1 | 0 | |a Lei Wang |e author |
700 | 1 | 0 | |a Min Jiang |e author |
700 | 1 | 0 | |a Yiman Lin |e author |
700 | 1 | 0 | |a Shisong Fang |e author |
700 | 1 | 0 | |a Bo Peng |e author |
700 | 1 | 0 | |a Weihua Wu |e author |
700 | 1 | 0 | |a Hui Liu |e author |
700 | 1 | 0 | |a Renli Zhang |e author |
700 | 1 | 0 | |a Patrick S. L. Kwan |e author |
700 | 1 | 0 | |a Qinghua Hu |e author |
245 | 0 | 0 | |a Comparative evaluation of six nucleic acid amplification kits for SARS-CoV-2 RNA detection |
260 | |b BMC, |c 2021-05-01T00:00:00Z. | ||
500 | |a 10.1186/s12941-021-00443-w | ||
500 | |a 1476-0711 | ||
520 | |a Abstract Background SARS-CoV-2 is a newly emerged coronavirus, causing the coronavirus disease 2019 (COVID-19) outbreak in December, 2019. As drugs and vaccines of COVID-19 remain in development, accurate virus detection plays a crucial role in the current public health crisis. Quantitative real-time reverse transcriptase-polymerase chain reaction (RT-qPCR) kits have been reliably used for detection of SARS-CoV-2 RNA since the beginning of the COVID-19 outbreak, whereas isothermal nucleic acid amplification-based point-of-care automated kits have also been considered as a simpler and rapid alternative. However, as these kits have only been developed and applied clinically within a short timeframe, their clinical performance has not been adequately evaluated to date. We describe a comparative study between a newly developed cross-priming isothermal amplification (CPA) kit (Kit A) and five RT-qPCR kits (Kits B-F) to evaluate their sensitivity, specificity, predictive values and accuracy. Methods Fifty-two clinical samples were used including throat swabs (n = 30), nasal swabs (n = 7), nasopharyngeal swabs (n = 7) and sputum specimens (n = 8), comprising confirmed (n = 26) and negative cases (n = 26). SARS-CoV-2 detection was simultaneously performed on each sample using six nucleic acid amplification kits. The sensitivity, specificity, positive/negative predictive values (PPV/NPV) and the accuracy for each kit were assessed using clinical manifestation and molecular diagnoses as the reference standard. Reproducibility for RT-qPCR kits was evaluated in triplicate by three different operators using a SARS-CoV-2 RNA-positive sample. On the basis of the six kits' evaluation results, CPA kit (Kit A) and two RT-qPCR Kits (Kit B and F) were applied to the SARS-CoV-2 detection in close-contacts of COVID-19 patients. Results For Kit A, the sensitivity, specificity, PPV/NPV and accuracy were 100%. Among the five RT-qPCR kits, Kits B, C and F had good agreement with the clinical diagnostic reports (Kappa ≥ 0.75); Kits D and E were less congruent (0.4 ≤ Kappa < 0.75). Differences between all kits were statistically significant (P < 0.001). The reproducibility of RT-qPCR kits was determined using a coefficients of variation (CV) between 0.95% and 2.57%, indicating good reproducibility. Conclusions This is the first comparative study to evaluate CPA and RT-qPCR kits' specificity and sensitivity for SARS-CoV-2 detection, and could serve as a reference for clinical laboratories, thus informing testing protocols amid the rapidly progressing COVID-19 pandemic. | ||
546 | |a EN | ||
690 | |a SARS-CoV-2 | ||
690 | |a COVID-19 | ||
690 | |a Nucleic acid detection | ||
690 | |a Real-time reverse transcriptase PCR (RT-qPCR) | ||
690 | |a Cross-priming isothermal amplification (CPA) | ||
690 | |a Therapeutics. Pharmacology | ||
690 | |a RM1-950 | ||
690 | |a Infectious and parasitic diseases | ||
690 | |a RC109-216 | ||
690 | |a Microbiology | ||
690 | |a QR1-502 | ||
655 | 7 | |a article |2 local | |
786 | 0 | |n Annals of Clinical Microbiology and Antimicrobials, Vol 20, Iss 1, Pp 1-6 (2021) | |
787 | 0 | |n https://doi.org/10.1186/s12941-021-00443-w | |
787 | 0 | |n https://doaj.org/toc/1476-0711 | |
856 | 4 | 1 | |u https://doaj.org/article/aca795eaa5464d6b961fa12a40ce0b51 |z Connect to this object online. |